Edition:
United States

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Global Market

8.21USD
17 Oct 2018
Change (% chg)

$-0.50 (-5.74%)
Prev Close
$8.71
Open
$8.63
Day's High
$8.63
Day's Low
$8.11
Volume
10,528
Avg. Vol
46,112
52-wk High
$11.47
52-wk Low
$4.30

Select another date:

Mon, Jul 30 2018

RedHill BioPharma has positive results from Crohn's disease trial

TEL AVIV Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.

RedHill BioPharma has positive results from Crohn's disease trial

TEL AVIV, July 30 Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.

BRIEF-Redhill Biopharma Posts Q1 Loss Of $0.05 Per Ordinary Share

* REDHILL BIOPHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Redhill Biopharma Says Last Patient Assessed For Main Goal In Late-Stage Crohn's Disease Trial

* REDHILL BIOPHARMA ANNOUNCES LAST PATIENT ASSESSED FOR PRIMARY ENDPOINT IN RHB-104 PHASE III STUDY FOR CROHN’S DISEASE

BRIEF-RedHill Biopharma Reports Enrollment of 300th Patient in Confirmatory Phase III Study With Talicia

* REDHILL BIOPHARMA ANNOUNCES ENROLLMENT OF 300TH PATIENT IN CONFIRMATORY PHASE III STUDY WITH TALICIA® FOR H. PYLORI INFECTION

Select another date: